Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
暂无分享,去创建一个
B. Strober | M. Lebwohl | C. Leonardi | C. Griffiths | Shu Li | C. Guzzo | N. Yeilding | J. Prinz | M. Hsu | P. Szapary